New Explorations in High-Risk AML Treatment: AZA Combined with HiDAC / Mito Regimen
Acute myeloid leukemia (AML) has a generally poor prognosis, with a 5-year survival rate of approximately 27%. Some subgroup studies indicate that patients with treatment-related AML (t-AML), older AML patients (aged ≥60 years), relapsed/refractory AML (R/R-AML) patients, and those who develop AML from other hematological diseases have worse prognostic outcomes. In high-risk AML patients, the … Read more
